Lycia Therapeutics Form 4 Filed by Versant Vantage II
A Form 4 for Lycia Therapeutics, Inc., for Oct. 26 was filed by Versant Vantage II, L.P. on October 28.
Related stories
Man Infraconstruction Q2 Profit Rises 8.7% to ₹65.2 Crore
Consolidated revenue increased 57.2% year on year to ₹266 crore for the September quarter, from ₹169 crore.
M impact | EQUITY | Oct 29, 2026, 09:53 AM UTC
Laurus Labs Q2 Profit More Than Doubles; Margin Beats Estimates
Laurus Labs said September-quarter net profit more than doubled year on year and revenue and operating earnings beat CNBC-TV18’s estimates. The company also declared a dividend and
M impact | EQUITY | Oct 29, 2026, 09:53 AM UTC
Zhongmin Baihui Retail Group Reports Annual General Meeting Results
The company reported the results of its annual general meeting. The headline also refers to a proposed renewal of the share buyback mandate; the supplied body is truncated.
M impact | EQUITY | Oct 29, 2026, 09:53 AM UTC
Portland General Electric Q3 Earnings Snapshot
Portland General Electric is the subject of a Q3 earnings snapshot; the supplied text does not include any reported results.
M impact | EQUITY | Oct 29, 2026, 09:52 AM UTC
ServiceNow Shares Fall Nearly 18% in Premarket Trading
ServiceNow shares fell nearly 18% in premarket trading after the company reported mixed third-quarter results, with revenue beating expectations and earnings falling short. JPMorga
M impact | EQUITY | Oct 29, 2026, 09:52 AM UTC
HDFC Bank indicative price falls 1.5%
HDFC Bank's indicative price is down 1.5%, extending pre-auction losses of 0.04%.
M impact | EQUITY | Oct 29, 2026, 09:51 AM UTC